Advarra’s institutional review board (IRB) members have extensive, varied backgrounds, including service on institutional, academic, and independent IRBs. This diverse membership ensures we hear the full range of ethical perspectives, and we maintain a network of consultants to provide additional insights when necessary. Members of the Advarra® IRBs are versed in examining research for its ethical implications, including research involving vulnerable populations such as pediatrics, critically ill, and cognitively impaired participants.

Review groups and service teams include scientists who have pioneered techniques, methodologies, and discoveries in their fields. Advarra synthesizes this deep expertise and commitment to review excellence across all therapeutic areas, and continues to set the standard for review services in areas such as oncology and neurology.

Advarra supports all phases of drug, device, and biologics development, as well as social, behavioral, and international research through:

  • Multiple daily IRB meetings to ensure timely review and response
  • Priority review meetings when needed
  • 24/7 access to the IRB submission management platform (the Advarra CIRBI® Platform)
  • Recruitment guidance for all media strategies and materials
  • On-call consultation on all aspects of the study submission and review process
  • Close collaboration with the Advarra operations team
  • Additional expert advice on protocol design through Advarra Consulting

Meeting Schedule

US review boards

Meetings daily (Monday through Friday)

Canadian review boards

Meetings 3x weekly (Tuesday, Wednesday, Friday)

IRB Review Determinations

Each study will be given one of the following designations:


The IRB approves the study as submitted for up to 1 year
(Not applicable for studies that do not require continuing review under the revised Common Rule)

Approved with Modifications

The IRB may approve research with modifications, also known as a “Conditional Approval,” with IRB-required restrictions or alterations of specific elements and/or documents


The IRB defers a decision on the study to seek additional information from the PI, sponsor/CRO, or a consultant


The IRB cannot approve the study and will issue a formal letter of disapproval stating the basis for its decision

In the case of an approved, approved with modifications, or deferred decision, the submitting party will be notified. Advarra’s IRB has the responsibility and authority to determine the adequacy and appropriateness of all the wording in the informed consent form. (See 21 CFR 56.109 and FDA’s A Guide to Informed Consent.) Advarra will provide proposed consent revisions to the submitting party.

Approval for studies and sites will last for the period specified in the approval documentation but will not exceed 1 year (not applicable for studies that do not require continuing review under the revised Common Rule). Advarra will specify the expiration date in your approval letter. The Advarra-approved consent will be included with the initial approval documents.

The IRB will issue a formal letter if the study is disapproved. The recipient has the right to submit a written appeal to the IRB. If you submit the study to a second IRB after disapproval by Advarra, you must notify the other IRB of Advarra’s disapproval.